# US 2026/0091036 A1 · Dosing Regimens for Elagolix

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091036 A1
- Document ID: US20260091036A1
- Status: Published application
- Kind: A1
- Application number: 19/310,386
- Filed: 2025-08-26
- Published: 2026-04-02
- Earliest claimed: 2018-08-01
- Applicants: AbbVie Inc.
- Inventors: Mohamad Shebley
- Web page: https://patentgrep.com/patent/US20260091036A1

## CPC

- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/00: Drugs for skeletal disorders
- C07D 239/54: as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

## Claims

### Claim 1

A method for treating a female subject with 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-di oxo-3,6-dihydro-2H-pyrimi din-1-yl1-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, the method comprising:
administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a first dosing schedule during a first treatment period; and
administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a second dosing schedule during a second treatment period, wherein the second dosing schedule comprises a lower dose and/or less frequent administration than the first dosing schedule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first treatment period is about three months or about six months.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second treatment period is from about eighteen to about twenty four months.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is suffering from endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first dosing schedule comprises twice daily administration of Compound A or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second dosing schedule comprises once daily administration of Compound A or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl benzyl 1)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl1-1-phenyl-ethylamino) butanoate.

### Claim 8

A method for treating a female subject with 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, the method comprising:
administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a first dosing schedule during a first treatment period, wherein the first dosing schedule comprises twice daily administration of about 200 mg of Compound A or a pharmaceutically acceptable salt thereof; and
subsequently administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a second dosing schedule during a second treatment period, wherein the second dosing schedule comprises once daily administration of about 150 mg of Compound A or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the first treatment period is not more than about six months.

### Claim 10 (depends on 8)

The method of claim 8, wherein the second treatment period is from about eighteen to about twenty four months.

### Claim 11 (depends on 8)

The method of claim 8, wherein the subject is suffering from endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids.

### Claim 12 (depends on 8)

The method of claim 8, wherein Compound A or a pharmaceutically acceptable salt thereof is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-di oxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl ethylamino) butanoate.

### Claim 13

A method for reducing the rate of bone mineral density loss in a subject treated with 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, the method comprising
administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a first dosing schedule during a first treatment period, wherein the first dosing schedule is associated with a first rate of bone mineral density loss;
subsequently administering Compound A or a pharmaceutically acceptable salt thereof to the subject according to a second dosing schedule during a second treatment period, wherein the second dosing schedule is associated with a second rate of bone mineral density loss that is reduced relative to the first rate of bone mineral density loss.

### Claim 14 (depends on 13)

The method of claim 13, wherein the second dosing schedule comprises a reduced dosage amount, dosing frequency, and/or total daily dose relative to the first treatment period.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first treatment period is about three months or about six months.

### Claim 16 (depends on 13)

The method of claim 13, wherein the second treatment period is from about eighteen to about twenty four months.

### Claim 17 (depends on 13)

The method of claim 13, wherein the subject is suffering from endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids.

### Claim 18 (depends on 13)

The method of claim 13, wherein Compound A or a pharmaceutically acceptable salt thereof is sodium 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino) butanoate.

### Claim 19

A method for treating uterine fibroids in a female subject in need thereof, the method comprising:
administering 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof to the subject during a treatment period, wherein the treatment period lasts for more than six months; and
co-administering a hormone add-back therapy during the treatment period.

### Claim 20 (depends on 19)

The method of claim 19, wherein the hormone add-back therapy comprises estradiol and norethindrone acetate.
